Description

Ajuben is a vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the treatment of- Chorea associated with Huntington's disease Tardive dyskinesia in adults. * রেজিস্টার্ড চিকিৎসকের পরামর্শ মোতাবেক ঔষধ সেবন করুন'

The precise mechanism by which deutetrabenazine exerts its anti-chorea effects is unknown but is believed to be related to its effect as a reversible depletor of monoamines (such as dopamine, serotonin, norepinephrine, and histamine) from nerve terminals. The major circulating metabolites (α-dihydrotetrabenazine and β-dihydrotetrabenazine) of deutetrabenazine, are reversible inhibitors of vesicular monoamine transporter 2 (VMAT2), resulting in decreased uptake of monoamines into synaptic vesicles and depletion of monoamine stores.

Patients not presently receiving Tetrabenazine: Chorea associated with Huntington’s disease- Initial dose: 6 mg/day Maintenance dose: 6 mg-48 mg/day Maximum dose: 48 mg/day Tardive dyskinesia- Initial dose: 12 mg/day Maintenance dose: 12 mg-48 mg/day Maximum dose: 48 mg/day Titrate up at weekly intervals by 6 mg per day to a tolerated dose that reduces chorea, up to a maximum recommended daily dosage of 48 mg (24 mg twice daily). Administer total daily dosages of 12 mg or above in two divided doses and administer with foods. * রেজিস্টার্ড চিকিৎসকের পরামর্শ মোতাবেক ঔষধ সেবন করুন'

Concomitant use of strong CYP2D6 inhibitors: Maximum recommended dose of Ajuben is 36 mg per day (18 mg twice daily) and alcohol or other sedating drugs- may have additive sedation and somnolence.

Deutetrabenazine is contraindicated in patients with Suicidal, or untreated/inadequately treated depression, Hepatic impairment and in patients Taking MAOIs, reserpine, or tetrabenazine.

Most common adverse reactions (>8%) of deutetrabenzine’s are somnolence, diarrhea, dry mouth, and fatigue.

There are no adequate data on the developmental risk associated with the use of deutetrabenazine in pregnant women. There are no data on the presence of deutetrabenazine or its metabolites in human milk, the effects on the breastfed infant, or the effects of the drug on milk production.

Patients may experience Neuroleptic Malignant Syndrome (discontinue Ajuben if this occurs), Akathisia, agitation, restlessness, and Parkinsonism (reduce the daily dose of Ajuben or discontinue if this occurs) and Sedation/somnolence.